Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimumab and JAKis no different at 12 months. 20-25% switching at 12-months. Clearly more to secondary failure than anti-drug antibodies.
@RheumNow #ACR22
Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors - ACR Meeting Abstracts
@RheumNow #ACR22
